Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature

Dermatol Online J. 2021 Apr 15;27(4):13030/qt0dv3f9h6.

Abstract

Bullous pemphigoid is an autoimmune skin disease that results in formation of pruritic blisters. Most cases are treated with a combination of systemic and topical corticosteroids as well as other immunomodulatory drugs. Dupilumab is a fully human monoclonal antibody that acts as an antagonist against IL4Ra traditionally used in the treatment of atopic dermatitis. We present an 80-year-old man with moderate to severe bullous pemphigoid successfully treated with dupilumab.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Drug Resistance
  • Glucocorticoids / therapeutic use
  • Humans
  • Interleukin-4 Receptor alpha Subunit / antagonists & inhibitors*
  • Male
  • Pemphigoid, Bullous / drug therapy*
  • Prednisone / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Interleukin-4 Receptor alpha Subunit
  • dupilumab
  • Prednisone